CN110684102A

CN110684102A - SFTSV detection kit

Info

Publication number: CN110684102A
Application number: CN201910885757.6A
Authority: CN
Inventors: 吴喜林; 吴稚伟; 李彦磊; 潘逸
Original assignee: Source Daolong (suzhou) Medical Technology Co Ltd
Current assignee: Source Daolong (suzhou) Medical Technology Co Ltd
Priority date: 2019-07-23
Filing date: 2019-09-19
Publication date: 2020-01-14
Anticipated expiration: 2039-09-19
Also published as: CN110713536A; CN110684102B; WO2021012195A1; CN112105637A; CN110713536B; JP7171737B2; KR20210013000A; KR102504884B1; JP2021534727A; CN112105637B

Abstract

The invention relates to an SFTSV detection kit, which comprises a detection antibody, a solid matrix and a coating antibody coated on the solid matrix, wherein the detection antibody and the coating antibody respectively comprise 3 complementarity determining regions CDR1-3, the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NO. 1-74, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NO. 75-151, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO. 152-232. The invention aims at SFTS with high lethality rate but lacking effective vaccine and specific antiviral drug to develop nano antibody drug development and diagnosis kit, screens the nano antibody VHH specifically combined with GN, identifies the CDR sequence, constructs humanized antibody SNB, provides potential nano antibody new drug for clinical treatment of SFTS, and provides corresponding detection kit for diagnosis of SFTS.

Description

SFTSV detection kit

PRIORITY CLAIM

This application claims priority from the international application No. PCT/CN2019/097350 filed on 23.7.2019 by the present applicant and incorporated herein by reference.

Technical Field

The invention relates to the field of biomedicine. More particularly, it relates to a polypeptide capable of binding SFTSV, the application of said polypeptide in preparing SFTSV detecting agent or SFTSV therapeutic medicine and a SFTSV detecting kit.

Background

The fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by a novel bunyavirus (SFTSV) and is mainly transmitted by tick bites or blood and mucous membrane contact of acute patients, and clinically, the fever, thrombocytopenia, leukopenia and multiple organ dysfunction including gastrointestinal tract, liver and kidney are mainly manifested. Since SFTS is reported in Hubei and Henan for the first time in 2009, case reports have been published in 16 provinces in China, the number of cases diagnosed in 2014 is over 3500, and the incidence rate is increased in recent years; meanwhile, SFTS cases are reported in korea, japan, arabian, and the united states, suggesting that the prevalence area of the disease is expanding. The currently reported mortality rate for SFTS is between 6.3% and 30%; and the mortality rates published in korea and japan in 2016 were as high as 35.4% and 50%, respectively. However, there is no specific therapeutic drug for SFTS in clinical practice, and only broad-spectrum antiviral therapy and symptomatic drug administration are available, which brings great difficulty to prevention and control of SFTS.

The specific neutralizing antibody has good clinical curative effect in antiviral treatment, such as respiratory syncytial virus monoclonal antibody Palivizumab, rabies virus antiserum and the like. Neutralizing antibodies against the SFTSV surface glycoprotein (glycoprotein n, GN) have been shown to play an important role in patient survival. Our earlier results also show that the serum anti-GN SFTS patients all recovered well, while the serum non-GN SFTS patients had a mortality rate as high as 66.7%. These studies suggest that neutralizing antibody therapy targeting GN would be an effective approach to combat SFTSV.

In 1993, a novel natural antibody derived from camelidae was found. The antibody naturally lacks a light chain and consists only of a heavy chain comprising two constant regions (CH2 and CH3), a hinge region and a heavy chain variable region (VHH, i.e., antigen binding site) with a relative molecular mass of about 13KDa, which is only 1/10 of conventional antibodies, and is the smallest functional antibody fragment currently available, both in molecular height and diameter at the nanometer level, and thus is also known as a Nanobody (Nb). Because the nano monoclonal antibody has the characteristics of high stability (not degraded at 90 ℃), high affinity, homology of more than 80 percent with a human antibody, low toxicity and immunogenicity and the like, the nano monoclonal antibody is widely applied to the research and development of immunodiagnosis kits, the research and development of imaging, and the research and development of antibody drugs aiming at the fields of tumors, inflammations, infectious diseases, nervous system diseases and the like.

The currently known SFTS neutralizing antibody against GN is Mab4-5 screened by phage display SFTS patient antibody library in 2013, with an IC50 of 2 μ g/ml to 44.2 μ g/ml. The lower the IC50 of neutralizing antibody, the better, can greatly save the use of antibody and save the production cost, and can also prolong the time of maintaining effective concentration of antibody in vivo. The antibody titer of the serum of the SFTS patient is detected in the previous period, and the antiserum aiming at the GN protein is only about 100 dilution times, which indicates that constructing an antibody library by using the serum of the SFTS patient with low antibody titer possibly limits the screening of high-efficiency neutralizing antibodies. Therefore, the SFTSV specific neutralizing antibody which is more efficient and stable and has lower IC50 is expected to be obtained through a novel technical means.

Disclosure of Invention

The camel source nanometer monoclonal antibody and the VHH thereof are obtained by immunizing camel with antigen and are used for diagnosing and treating acute infection SFTS patients. Based on these studies, the present invention provides a polypeptide capable of binding to SFTSV, which comprises 3 complementarity determining regions CDR1-3, wherein the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NOS: 1-74, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NOS: 75-151, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO: 152-232.

The invention provides an SFTSV detection kit, which comprises a detection antibody, a solid substrate and a coating antibody coated on the solid substrate, wherein the detection antibody and the coating antibody are respectively one of the polypeptides.

In a specific embodiment, the CDR sequences of the detection antibody are as follows:

the sequence of CDR1 is SEQ ID NO. 4, the sequence of CDR2 is SEQ ID NO. 84, and the sequence of CDR3 is SEQ ID NO. 181; or

The sequence of CDR1 is SEQ ID NO:54, the sequence of CDR2 is SEQ ID NO:132, and the sequence of CDR3 is SEQ ID NO: 176; or

The sequence of CDR1 is SEQ ID NO 13, the sequence of CDR2 is SEQ ID NO 99, and the sequence of CDR3 is SEQ ID NO 166.

In a specific embodiment, the CDR sequences of the coated antibody are as follows:

The sequence of CDR1 is SEQ ID NO. 54, the sequence of CDR2 is SEQ ID NO. 132, and the sequence of CDR3 is SEQ ID NO. 176; or

CDR1 has the sequence of SEQ ID NO 6, CDR2 has the sequence of SEQ ID NO 81, and CDR3 has the sequence of SEQ ID NO 158; or

In a preferred embodiment of the process according to the invention,

I) the CDR sequences of the detection antibody are as follows: the sequence of CDR1 is SEQ ID NO. 4, the sequence of CDR2 is SEQ ID NO. 84, and the sequence of CDR3 is SEQ ID NO. 181; or the sequence of CDR1 is SEQ ID NO 13, the sequence of CDR2 is SEQ ID NO 99, and the sequence of CDR3 is SEQ ID NO 166;

and the number of the first and second electrodes,

II) the CDR sequences of the coated antibody are as follows: the sequence of CDR1 is SEQ ID NO. 4, the sequence of CDR2 is SEQ ID NO. 84, and the sequence of CDR3 is SEQ ID NO. 181; or the sequence of CDR1 is SEQ ID NO 54, the sequence of CDR2 is SEQ ID NO 132, and the sequence of CDR3 is SEQ ID NO 176; or the sequence of CDR1 is SEQ ID NO 6, the sequence of CDR2 is SEQ ID NO 81, and the sequence of CDR3 is SEQ ID NO 158; or the sequence of CDR1 is SEQ ID NO 13, the sequence of CDR2 is SEQ ID NO 99, and the sequence of CDR3 is SEQ ID NO 166.

In a preferred embodiment of the process according to the invention,

I) the sequence of the detection antibody CDR1 is SEQ ID NO. 4, the sequence of the CDR2 is SEQ ID NO. 84, and the sequence of the CDR3 is SEQ ID NO. 181; and is

II) the CDR sequences of the coated antibody are as follows: the sequence of CDR1 is SEQ ID NO. 54, the sequence of CDR2 is SEQ ID NO. 132, and the sequence of CDR3 is SEQ ID NO. 176; or the sequence of CDR1 is SEQ ID NO 13, the sequence of CDR2 is SEQ ID NO 99, and the sequence of CDR3 is SEQ ID NO 166.

In a further preferred embodiment of the process according to the invention,

I) the sequence of the detection antibody CDR1 is SEQ ID NO. 13, the sequence of the CDR2 is SEQ ID NO. 99, and the sequence of the CDR3 is SEQ ID NO. 166; and is

The CDR sequences of the coated antibody are as follows:

the sequence of CDR1 is SEQ ID NO. 4, the sequence of CDR2 is SEQ ID NO. 84, and the sequence of CDR3 is SEQ ID NO. 181; or the sequence of CDR1 is SEQ ID NO 54, the sequence of CDR2 is SEQ ID NO 132, and the sequence of CDR3 is SEQ ID NO 176; or the sequence of CDR1 is SEQ ID NO 6, the sequence of CDR2 is SEQ ID NO 81, and the sequence of CDR3 is SEQ ID NO 158; or the sequence of CDR1 is SEQ ID NO 13, the sequence of CDR2 is SEQ ID NO 99, and the sequence of CDR3 is SEQ ID NO 166.

The invention aims at SFTS with high fatality rate but lacking effective vaccine and specific antiviral drug to develop nano antibody drug development and diagnosis kit, and selects nano antibody VHH specifically combined with GN by preparing GN protein, immune doublet camel, platform technology for displaying nano monoclonal antibody by using phage library, etc., identifies CDR sequence thereof, and constructs humanized VHH-huFc1 (SNB); at the same time, the humanized mouse model is used for evaluating the curative effect of SNB in the treatment of SFTSV infection in vivo. The invention provides a potential nano antibody new drug for the clinical treatment of SFTS, and simultaneously provides a corresponding detection kit for the diagnosis of SFTS.

Drawings

FIG. 1 is a curve of the antiserum titer detection at sGN after one week of 3rd and 4 th immunisation of camels;

FIG. 2 is a graph of the inhibition of SFTSV virus infection of Vero cells in vitro by antiserum one week after the 4 th immunization of camels at different dilutions, compared to preimmune serum;

FIG. 3 is an electrophoretogram of PCR products amplified using sGN-VHH phage antibody library as a template;

FIG. 4 is a panning identification of sGN-VHH phage antibody library, wherein A is a statistical plot of ELISA detection after panning of phage library against sGN protein; b is the second wheel (2)^nd) And a third wheel (3)^rd) 96 clones are selected from the panned phage antibody library respectively to carry out phage ELISA detection statistical chart;

FIG. 5 is a statistical ELISA assay for prokaryotically expressed VHH antibodies, each dot representing a clone, with OD450 for sGN/OD 450 for the blank plotted on the ordinate, and a positive value for a ratio greater than 5.0;

FIG. 6 is a statistical chart of experiments on neutralization of SFTSV virus infection by positive VHH antibodies, one dot representing one clone, and the Y-axis being the relative inhibition rate for different viruses;

FIG. 7 shows an ELISA assay for binding of SNB to sGN protein at different purified concentrations, with different colors representing different clone numbers.

FIG. 8 is a photograph of fluorescent staining of SFTSV virus in the presence of different concentrations of antibody, with fluorescent spots representing SFTSV virus, virus-free cells as a No infection control (No infection control), and virus-free cells without antibody as an infection control (infection control);

FIG. 9 is a graph of the inhibition of SFTSV virus by antibodies obtained from the fluorescent spots counted in FIG. 7;

FIG. 10 is a statistical graph of the relative inhibition rates of different mice after challenge, the relative inhibition rates being 1-day 9/day 6 viral loads, with human immunoglobulin as the control (Hu-IgG);

FIG. 11 is a statistical view of the detection of sGN protein by SNB double antibody sandwich ELISA, in which SNB01(A), SNB02(B) and SNB37(C) are used as detection antibodies, respectively; d is coating antibody SNB01, and the double antibody sandwich ELISA for detecting antibody SNB37 detects OD450 statistical curves of sGN at different concentrations.

FIG. 12 is a statistical curve of OD450 of SFTSV virus at different concentrations detected by double antibody sandwich ELISA, which includes coating antibody SNB01 and detecting antibody SNB 37.

Detailed Description

1. Preparation of immunogens

Based on GN protein sequence and gene sequence information of HB29SFTSV on NCBI website, we analyzed and designed polypeptide sGN capable of effectively inducing camel to generate specific antibody against GN protein, and connected His-tag (sGN-His) or rabbit Fc (sGN-rFc) at C terminal for subsequent purification and detection.

2. Camel immunization and antiserum procurement

Priming a doublet camel with an emulsified mixture of 250 mu g of sGN-rFc protein and 250 mu l of Freund's complete adjuvant, boosting the camel with sGN-rFc protein and 250 mu l of Freund's incomplete adjuvant 3 times on days 14, 28 and 42, and collecting blood to detect the antiserum titer 1 week after 2 and 3 weeks of immunization; after 1 week of the 4 th immunization, 200ml of blood was collected for the construction of phage antibody library.

Antiserum titers were measured by ELISA, assay plates were coated with GN protein at a concentration of 0.5 μ g/ml, and either antiserum diluted in a gradient or purified antibody 100 μ l (control was pre-immune camel serum) was added to each well, incubated at 37 ℃ for 1.5h, washed 2 times, and 1: 10000 diluted horse radish peroxidase labeled Goat anti-Llama IgG (H + L) secondary antibody, incubating at 37 deg.C for 1H, washing for 4-6 times, adding 100 μ L TMB substrate, incubating at 37 deg.C for 10min,50 μ l of 0.2M H₂SO₄The reaction was stopped and OD450nm was measured. ELISA assay serum titers were specified at the highest dilution of OD450 above 2.1-fold of blank and greater than 0.2.

As shown in FIG. 1, the antiserum titers of 3-and 4-immunization were 2.19X 10, respectively⁶And 4.61X 10⁶. It can be seen that this antigen can induce camels to produce high titers of antisera specific for GN protein.

To further verify whether this high titer camelid antiserum was effective in preventing SFTSV virus infection, neutralization experiments for virus infection were performed. Antiserum and preimmune serum with different dilution concentrations are respectively incubated with the SFTSV virus for 60min, then transferred to Vero cells, and after 48h, the infection of the SFTSV is judged by cell immunofluorescence staining of sGN protein. The results of the neutralization experiments showed that sGN-induced antisera inhibited 90% of SFTSV infection by more than 540-fold dilution of ID90 (FIG. 2). Taken together, sGN induced high titers of antisera that had the ability to inhibit SFTSV virus infection at high levels.

Construction and panning of VHH phage library

Collecting 200ml of camel peripheral blood after immunization, separating by using lymphocyte separation liquid (GE Ficoll-Paque Plus) to obtain camel PBMC, extracting RNA according to a TRIzol operation manual, inverting by using oligo (dT) into cDNA, cloning the camel VHH gene to phagemid plasmid by using techniques such as primer amplification, molecular cloning and the like, and transforming TG1 bacteria to obtain the VHH phage library. To further identify sGN-VHH phage library was successfully constructed, by PCR amplification of the VHH gene of the immune sGN camelid, it was shown that the band of interest was 500bp, with the expected size (FIG. 3), indicating that the sGN-VHH phage antibody library contained VHH genes. Selecting 50 clones for sequencing, wherein the sequencing result shows that the sequenced sequences do not have completely consistent repeated sequences; the alignment results show that the most of the different sequences are in the CDR binding region. Through detection, the library capacity of the sGN-VHH phage antibody library is 2.0 x10⁹The positive rate is 100%, the sequence Diversity (Diversity) is 100%, and the effective insertion rate (In frame rate) is greater than 95%.

The phage antibody library was recovered from VHH-phagemid transformed bacteria with the help of M13KO7 helper phage and precipitated with PEG/NaCl. The sGN-His protein coated with 50. mu.g/ml was subjected to three enrichment of phage antibody libraries. And (3) carrying out elution, transformation, plate coating and monoclonal picking on the enriched phage, carrying out binding identification on the phage and sGN protein ELISA, sequencing the clone with the binding reading value of more than 1.0, cloning to an expression vector pVAX1, and transfecting 293F cells to express to produce the nano monoclonal antibody.

The panned library was tested for binding to GN protein. The phage ELISA results showed that the binding reading values of the sGN-VHH phage library before enrichment and sGN protein were 0.57, and the reading values of the phage library after one, two and three rounds of enrichment were 0.98, 2.2 and 3.0, respectively (FIG. 4A). To further verify the positive phage rate of sGN-VHH protein binding in the enriched library, 96 clones were selected from each of the 2nd and 3rd round enriched libraries for single phage ELISA detection. The results showed that 24.5% of the individual phage clones were positive in the library round 2 and 67% of the phage clones were positive in the library round 3, and that the mean reading for binding was around 3.0 (FIG. 4B), and that the high binding sGN-VHH phage library was successfully enriched by protein panning at sGN.

Construction of VHH prokaryotic expression library and VHH expression

PCR amplification of the enriched 2nd-sGN-VHH and 3rd-sGN-VHH phage antibody libraries from the two and three rounds of panning described above; obtaining and purifying all VHH gene fragments in an antibody library, cloning the VHH gene fragments to a prokaryotic expression vector, converting an SS320 strain, and constructing a prokaryotic expression antibody library of the VHH; coating a plate with the prokaryotic expression antibody library, culturing overnight, randomly selecting 1000 monoclonal colonies the next day, inducing expression of antibody supernatant by IPTG, and carrying out ELISA binding detection on the antibody supernatant and sGN protein.

The results show that there was bacterial supernatant that bound sGN protein while not binding to the blank, and that sGN bound reads/blank reads greater than 5.0 (figure 5 and table 1). These sequences were sequenced and aligned to eliminate repeated sequences, and 142 VHH antibody sequences (SEQ ID NOS: 1-142) were finally obtained. Further experiments demonstrated that both the 142 VHH antibodies and CDRs derived from the VHH antibodies can specifically bind to SFTSV virus.

TABLE 1142 binding values of VHH antibodies to sGN protein and sequences thereof

In order to further verify whether the sequence can well inhibit the SFTSV virus infection, bacterial supernatants of 122 VHH antibodies are treated and incubated with the SFTSV virus, and whether the antibodies can inhibit the SFTSV virus infection is tested. The results of the neutralization experiments (fig. 6) show that 23 antibodies can achieve an inhibitory effect of more than 50%. The antibody numbers are G77, G78, G79, G87, G95, G103, G109, G111, G112, G113, G114, G116, G117.1, G121, G124, G125, G126, G131, G133, G145, G170, and G171, respectively.

Eukaryotic expression of VHH-huFc (SNB)

Through a molecular cloning technology, the 23 nanometer monoclonal antibody VHH genes are fused with human Fc genes and inserted into a pVAX1 eukaryotic expression vector to construct and form an Nb-huFc-pVAX1 expression plasmid. The constructed Nb-huFc-pVAX1 is transfected into 293F cells, expressed to produce Nb-huFc (SNB), and purified by Protein G. The purified VHH-huFc1(SNB) antibodies were collected and tested in an ELISA assay, with some antibodies having good binding capacity (fig. 7). The respective sequence numbers of the constructed humanized antibodies are shown in Table 2.

TABLE 2 original antibody numbering and CDR sequences corresponding to humanized antibodies SNB

Coupling 4000RU of sGN protein to CM5 chips by BIAcore x100 instrument according to the amino coupling kit instructions; ethanolamine blocks the coupled chip. Antibody was diluted in a gradient to different concentrations. The Bioevaluationversion 4.0 software sets the test program: detecting the concentration of the antibody from low concentration to high concentration, and performing 2 repeated detections on each concentration; the binding time was set to 180 seconds and the flow rate was 30. mu.l/min; the dissociation time was set to 180 seconds and the flow rate was 30. mu.l/min; setting the flow rate of glycine with the pH value of 2.510mM as 30 mul/min for 30 seconds, and activating and regenerating the surface of the chip; PBS was equilibrated for 5 seconds and the flow rate was 30. mu.l/min. The experimental data were analyzed to obtain binding, dissociation and affinity constants. As a result, as shown in Table 3, the affinity of most antibodies reached 10^-9(Nano-mole grade), with two antibodies SNB02 and SNB07 reaching 10^-10(Pico mole grade). It can be seen that we obtained VHH-huFc1(SNB) antibodies with high affinity.

Table 3 summary of SNB affinities.

Note: ka is the binding constant, KD is the dissociation constant, and KD is the affinity.

SNB-neutralizing SFTSV infection of Vero cells

SNB02 and SNB16 in VHH-huFc1 were selected for in vitro neutralization experiments. Antibodies were diluted in gradient to different concentrations, together with SFTSV virus, at 5% CO₂Incubated at 37 ℃ for 1 hour, and 1.5X10 added⁴Vero cells, 5% CO₂After incubation at 37 ℃ for 48 hours in an incubator, the cell supernatant was removed, fixed with 4% paraformaldehyde for 15min, washed and blocked, and then added with Rabbit polyclonal serum against GN (1:1000 dilution), overnight at 4 ℃, washed with PBST, and then incubated with 50. mu.l of a secondary antibody against Rabbit (Alexa Fluor 488Anti-Rabbit IgG (H + L), Code:111-Taking a picture by a microscope for observation, counting green spots and calculating the neutralization inhibition rate and the neutralization titer by the fluorescence intensity, wherein the inhibition rate is [1- (the fluorescence intensity mean value of the sample group-the fluorescence intensity mean value of the cell control group CC)/(the fluorescence intensity mean value of the control treatment group-the fluorescence intensity mean value of the cell control group CC)]X 100%. Neutralizing titer (ID)₅₀Or ND₅₀) Expressed as a multiple of the dilution at 50% inhibition.

As shown in FIGS. 8 and 9, SNB02 has excellent neutralizing activity, and the inhibition rate reached 83.5% at an antibody concentration of 9. mu.g/ml. The efficacy of SNB02 was evaluated using a humanized mouse model.

SNB treatment of SFTS in vivo infections

Cg-prkdcsccill 2rgtm1Wjl/szj (ncg) mice, purchased from university of tokyo model animals, were deleted of the IL2 receptor gene on a SCID mouse basis, similar to NSG mice, resulting in the absence of mouse T cells, B cells, and very few NK cells in vivo. 1.0-15x10⁷PBMC were injected intraperitoneally into NCG mice for 4-6 weeks; three weeks later, human T cells were flow-tested by collecting blood and staining human CD45⁺、CD3⁺、CD4⁺And CD8⁺. The proportion of human CD45 positive cells reached 5% or more, and the mice were judged to be successfully humanized. Inoculation 2X10⁷TCID50, 3 and 6 days after infection, were treated with 400. mu.g of SNB02 antibody/mouse (the amount of antibody was about 20mg/kg mouse) by intraperitoneal injection. Blood was collected before and on day 9 of each antibody treatment, and the viral load in the blood of mice was examined to determine whether the mice were successfully infected with SFTS virus and whether the SNB antibody could control SFTSV infection of the mice, using human IgG as a control. As shown in fig. 11, after three days of treatment (day 9), the viral load in the mice was measured, and the viral load in 9 mice and 7 mice treated with SNB02 was well suppressed, whereas in the control mice treated with Hu-IgG, SFTS virus proliferated in vivo, and the two groups were analyzed for the virus inhibition rate, and SNB02 significantly controlled SFTS virus infection (fig. 10).

8. In vivo experiments using AAV viral vector loaded SNB02

Adeno-associated virus (AAV) is derived from non-pathogenic wild adeno-associated virus, and is considered one of the most promising gene transfer vectors due to its high safety, wide host cell range (dividing and non-dividing cells), low immunogenicity, and long time for expressing foreign genes in vivo, and is widely used in gene therapy and vaccine research worldwide.

AAV Helper-Free viral packaging system was purchased from Cell Biolabs, San Diego USA. Inserting the DNA coding sequence of SNB02 into pAAV-MCS plasmid by molecular cloning technology; after the successful construction is proved by sequencing, the constructed plasmid pAAV-Ab and pHelper and pAAV-DJ plasmids are used for co-transfecting AAV-293T cells by using a PEI transfection reagent according to the mass ratio of 1:1: 1. Supernatants were collected at 48, 72, 96 and 120 hours post transfection and concentrated with 5xPEG8000(sigma) and finally purified with 1.37g/ml cesium chloride. Purified AAV was dissolved in PBS, identified and stored at-80 ℃ after packaging.

The humanized mice were inoculated with 2x10⁷SFTSV Virus of TCID50, collected on day 3 post infection and received AAV-SNB02(1X 10)¹¹gc/100. mu.l) were injected intramuscularly and blood was collected on days 6, 9 and 12, and viral load was measured with AAV-GFP as a control group. The results show that the SFTSV viral load was low in mice injected with AAV-SNB02, while the SFTSV virus was highly propagated in control mice.

9. Double antibody sandwich ELISA

Coating the detection plate with SNB antibodies with different concentrations, incubating at 37 ℃ for 2h and washing for 2-4 times, blocking with 10% bovine serum, incubating at 37 ℃ for 1h and washing for 2-4 times, adding protein and virus or sample diluted in gradient to each well for 100. mu.l, incubating at 37 ℃ for 1.5h and washing for 2 times, adding 1: 200-1: 10000 diluted 100 μ l of SNB antibody labeled by horseradish peroxidase, incubating at 37 deg.C for 1H, washing for 4-6 times, adding 100 μ l of TMB substrate, incubating at 37 deg.C for 10min, and 50 μ l of 0.2M H₂SO₄The reaction was stopped and OD450nm was measured. The positive samples for the ELISA test were specified to be the most potent samples with OD450 greater than 2.1 times that of the blank control (i.e., no coated assay antigen, labeled Neg in the figure) and with optical density values greater than 0.2High dilution factor.

The results showed that when the coating antibody was SNB02 or SNB07 and the detection antibody was SNB01, the combination was able to recognize sGN protein and negative control protein (fig. 11A); when the detection antibody was SNB02, the ELISA detection background was high (fig. 11B); when the detection antibody was SNB37 and the coating antibodies were SNB01, SNB02 and SNB07, the ELISA recognized sGN protein and the negative control protein (fig. 11C). The SNB antibody can be applied to the development of a double antibody sandwich ELISA sGN detection kit, wherein the detection sensitivity of the double antibody combination of SNB01 and SNB37 is 3.9ng/ml (FIG. 11D). The sensitivity of the combination for detecting SFTSV euvirus is measured to be 3.75x10⁶gc/ml (FIG. 12), which shows that the kit can detect not only SFTSV euviruses but also SFTSV euviruses with copy numbers as low as 10^ 6. Therefore, the nano antibody double-antibody sandwich detection kit can be applied to SFTSV virus infection detection.

The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Sequence listing

<110> Source daolong (Suzhou) medical science and technology, Inc

<120> SFTSV detection kit

<150>PCT/CN2019/097350

<151>2019-07-23

<160>237

<170>SIPOSequenceListing 1.0

<210>1

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>1

Gly Phe Thr Phe Asp Asp Ser Asn

1 5

<210>2

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>2

Gly His Thr Leu Ser Ser Asn Cys

1 5

<210>3

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>3

Gly Pro Phe Tyr Asn Thr His Cys

1 5

<210>4

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>4

Gly Asp Thr Ser Thr Ala Tyr Tyr

1 5

<210>5

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>5

Gly Asp Thr Tyr Ser Ser Ser Cys

1 5

<210>6

<211>5

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>6

Gly Phe Thr Ser Cys

1 5

<210>7

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>7

Gly Val Thr Leu Asp Asp Phe Leu

1 5

<210>8

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>8

Gly Val Thr Leu Asp Asp Phe Leu

1 5

<210>9

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>9

Gly Tyr Thr Phe Ser Asn Thr Cys

1 5

<210>10

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>10

Gly Arg Thr TyrArg Thr Tyr Cys

1 5

<210>11

<211>15

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>11

Glu Asp Ala His Ser Thr Thr Glu Tyr Ile Val Ser Thr Thr Cys

1 5 10 15

<210>12

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>12

Gly Val Thr Tyr Gly Ser Tyr Cys

1 5

<210>13

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>13

Gly Phe Thr Leu Ser Met Tyr Asp

1 5

<210>14

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>14

Glu Tyr Thr Gly Ser Arg Asn Cys

1 5

<210>15

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>15

Gly Tyr Thr Tyr Asn Asn Tyr Arg

1 5

<210>16

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>16

Gly Leu Tyr Tyr Pro Pro Leu Cys

1 5

<210>17

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>17

Arg Tyr Asp Tyr Ser Arg Thr Cys

1 5

<210>18

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>18

Gly Phe Thr Val Ser Arg Tyr Asp

1 5

<210>19

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>19

Gly Ser Ala Tyr Ser Thr Asn Cys

1 5

<210>20

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>20

Gly Tyr Thr Tyr Ser Ser Asn Cys

1 5

<210>21

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>21

Gly Phe Thr Phe Asn Ala Tyr Asp

1 5

<210>22

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>22

Val Tyr Thr Tyr Arg Gly Asn Asn

1 5

<210>23

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>23

Arg Tyr Thr Pro Thr Ile Thr Arg

1 5

<210>24

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>24

Val Tyr Thr Ser Ser Thr Met Trp

1 5

<210>25

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>25

Gly Tyr Thr Ser Thr Ala Tyr Tyr

1 5

<210>26

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>26

Gly Gly Thr Ser Thr Ala Tyr Tyr

1 5

<210>27

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>27

Gly Phe Thr Ser Ser Asn Tyr Asp

1 5

<210>28

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>28

Gly Phe Thr Ser Ser Ser Cys Gly

1 5

<210>29

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>29

Gly Tyr Thr Tyr Ser Ser Val Cys

1 5

<210>30

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>30

Gly Tyr Thr Tyr Asn Thr Ala Tyr

1 5

<210>31

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>31

Gly Tyr Ala Tyr Ser Thr Tyr Cys

1 5

<210>32

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>32

Gly Tyr Thr Tyr Asn Glu Tyr Ser

1 5

<210>33

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>33

Gly Tyr Asn Phe Asn Asn Val Cys

1 5

<210>34

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>34

Glu Tyr Thr Arg Ser Ser Arg Cys

1 5

<210>35

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>35

Gly Ser Thr Asp Ser Arg Arg Cys

1 5

<210>36

<211>13

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>36

Gly Tyr Pro Tyr Ser Ser Lys Thr Tyr Thr Asn Asn Cys

1 5 10

<210>37

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>37

Arg Tyr Ser Ser Ser Arg Arg Cys

1 5

<210>38

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>38

Gly Tyr Ile Tyr Asn Asp Tyr Phe

1 5

<210>39

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>39

Thr Tyr Asn Tyr Glu Ser Ser Gln

1 5

<210>40

<211>5

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>40

Thr Thr Thr Asn Tyr

1 5

<210>41

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>41

Gly Tyr Thr Tyr Asn Tyr Tyr Cys

1 5

<210>42

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>42

Gly Tyr Thr Tyr Tyr Asn Ser Asn Cys

1 5

<210>43

<211>10

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>43

Gly Gly Ser Val Thr Thr Gly Asn Tyr Tyr

1 5 10

<210>44

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>44

Gly Tyr Thr Phe Asn Thr Arg Cys

1 5

<210>45

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>45

Leu Tyr Thr Tyr Ser Tyr Asn Cys

1 5

<210>46

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>46

Gly Phe Thr Ser Asn Ser Cys Gly

1 5

<210>47

<211>7

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>47

Gly Met Met Ser Asn Ala Cys

1 5

<210>48

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>48

Gly Tyr Thr His Ser Ser Asp Ser

1 5

<210>49

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>49

Arg Ser Val Asn Arg Asp Thr Cys

1 5

<210>50

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>50

Ala Phe Ile Ser Asn Asn His Cys

1 5

<210>51

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>51

Gly Phe Thr Phe Ser Ser Tyr Asp

1 5

<210>52

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>52

Gly Phe Thr Phe Asp Asp Ser Asp

1 5

<210>53

<211>4

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>53

Gly Tyr Arg Cys

1

<210>54

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>54

Ala Tyr Thr Tyr Arg Gly Asn Asn

1 5

<210>55

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>55

Gly Ala Thr Tyr Asn Ile Asn Phe

1 5

<210>56

<211>7

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>56

Gly Tyr Thr Tyr Ser Asn Tyr

1 5

<210>57

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>57

Gly Phe Thr Phe Ser Ser Tyr Tyr

1 5

<210>58

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>58

Gly Ser Ile Tyr Ser Ser Asn Ala

1 5

<210>59

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>59

Gly Tyr Thr Tyr Ser Ser Ala Cys

1 5

<210>60

<211>7

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>60

Gly Met Tyr Ser Asn Thr Cys

1 5

<210>61

<211>10

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>61

Gly Gly Ser Ile Thr Thr Asn Tyr Tyr Gly

1 5 10

<210>62

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>62

Gly Asp Ser Ser Thr Ala Tyr Tyr

1 5

<210>63

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>63

Gly Asn Thr Tyr Thr Ser Ser Cys

1 5

<210>64

<211>10

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>64

Gly Gly Ser Ile Thr Thr Ala Gly Tyr Gly

1 5 10

<210>65

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>65

Gly Leu Tyr Tyr Leu Pro Leu Cys

1 5

<210>66

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>66

Gly Leu Trp His Pro Pro Leu Cys

1 5

<210>67

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>67

Gly Tyr Thr Tyr Gly Ser Tyr Cys

1 5

<210>68

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>68

Gly Leu Tyr Tyr Ser Pro Leu Cys

1 5

<210>69

<211>5

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>69

Arg Tyr Thr Ser Ser

1 5

<210>70

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>70

Gly Tyr Arg Tyr Asn Ala Cys Ser

1 5

<210>71

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>71

Gly Asn Pro Ser Gly Arg Lys Phe

1 5

<210>72

<211>11

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>72

Gly Ser Ser Gly Leu Ile Phe Ser Gly Ser Ala

1 5 10

<210>73

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>73

Glu Asp Thr Ser Thr Ala Tyr Tyr

1 5

<210>74

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>74

Gly Tyr Thr Tyr Ser Ser His Cys

1 5

<210>75

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>75

Ile Lys Ser Asp Gly Ser Thr Ser

1 5

<210>76

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>76

Ile Tyr Thr Gly Gly Gly His Thr Tyr

1 5

<210>77

<211>7

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>77

Val Tyr Pro His Leu Thr Tyr

1 5

<210>78

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>78

Ile Tyr Arg Gly Gly Arg Ala Thr Val

1 5

<210>79

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>79

Ile Cys Ser Asp Gly Ser Ala Ala

1 5

<210>80

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>80

Ile Tyr Arg Gly Gly His Ser Thr Val

1 5

<210>81

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>81

Ile Tyr Thr Arg Asp Gly Arg Pro Tyr

1 5

<210>82

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>82

Ile Asp Ser Glu Gly Arg Ile Asp

1 5

<210>83

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>83

Ile Asp Ser Gly Gly Ser Ser Ser

1 5

<210>84

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>84

Ile Tyr Arg Gly Gly Arg Ser Thr Val

1 5

<210>85

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>85

Ile Asp Arg Ser Gly Ser Ala Ser

1 5

<210>86

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>86

Ile Thr Ala Leu Ser Ala Thr Ser

1 5

<210>87

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>87

Thr Tyr Arg His Gly Gly Thr Thr Val

1 5

<210>88

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>88

Leu Glu Ser Asp Gly Ser Thr Ser

1 5

<210>89

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>89

Ile Tyr Thr Ser Gly Arg Arg Pro Trp

1 5

<210>90

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>90

Ile Phe Arg Gly Gly Arg Ser Thr Val

1 5

<210>91

<211>12

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>91

Ile Ser Ile Leu Tyr Ser Gly Ile Thr Val Ser Tyr

1 5 10

<210>92

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>92

Ile Ser Ala Gly Gly Asp His Thr Tyr

1 5

<210>93

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>93

Ile Asp Arg Asp Gly Ser Thr Ser

1 5

<210>94

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>94

Ile Cys Ser Asp Gly Ser Thr Ser

1 5

<210>95

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>95

Ile Phe Val Ser Gly Arg Ser Pro Trp

1 5

<210>96

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>96

Ile Tyr Arg Asp Asp Gly Thr Thr Tyr

1 5

<210>97

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>97

Ile Tyr Thr Gly Gly Gly Ser Thr Tyr

1 5

<210>98

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>98

Ile Phe Arg Ser Gly Arg Thr Ser Trp

1 5

<210>99

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>99

Ile Phe Thr Ser Gly Arg Arg Pro Trp

1 5

<210>100

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>100

Ile Thr Ser Thr Gly Thr Arg Gln Tyr

1 5

<210>101

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>101

Ile Tyr Thr Arg Gly Asp Arg Thr Phe

1 5

<210>102

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>102

Ile Tyr Arg Gly Asn Gly Ala Thr Gly

1 5

<210>103

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>103

Ile Trp Arg Gly Gly His Ser Thr Leu

1 5

<210>104

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>104

Ile Phe Ser Ser Gly Arg Arg Pro Trp

1 5

<210>105

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>105

Leu His Thr Asp Gly Leu Thr Ser

1 5

<210>106

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>106

Ile Phe Thr Ser Gly Arg Arg Ser Trp

1 5

<210>107

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>107

Ile Tyr Thr Ala Thr Gly Arg Thr Tyr

1 5

<210>108

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>108

Ile Asp Ser Asp Gly Ser Thr Ser

1 5

<210>109

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>109

Ile Asp Ser Asp Gly Val Thr Asp

1 5

<210>110

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>110

Ile Asn Ser Val Gly Arg Thr Arg

1 5

<210>111

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>111

Ile Tyr Thr Ser Ile Gly Arg Thr Tyr

1 5

<210>112

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>112

Ile Glu His Asp Gly Lys Ile Ile

1 5

<210>113

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>113

Ile Tyr Arg Gly Ser Gly Thr Thr His

1 5

<210>114

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>114

Ile Tyr Leu Ala Asn Gly Ala Thr Tyr

1 5

<210>115

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>115

Ile Tyr His Gly Asp Gly Thr Thr Tyr

1 5

<210>116

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>116

Ile Gly Ser Asp Gly Thr Thr Lys

1 5

<210>117

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>117

Val Ser Pro Arg Gly Glu Ser Ile Tyr

1 5

<210>118

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>118

Ile Phe Ser Ser Arg Asp Tyr Thr Asp

1 5

<210>119

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>119

Ile Asp Thr Gly Gly Ser Thr Tyr

1 5

<210>120

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>120

Ile Tyr Thr Arg Asp Ser Arg Thr Tyr

1 5

<210>121

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>121

Ile Thr Ala Ser Gly Ser Thr Tyr

1 5

<210>122

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>122

Ile Ser Ala Gly Gly Ile Ser Ile Asp

1 5

<210>123

<211>10

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>123

Trp Gly Ser Val Gly Ser Ser Thr Thr Tyr

1 5 10

<210>124

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>124

Ile Phe Ser Asp Gly Glu Thr Ala

1 5

<210>125

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>125

Ile Tyr Thr Gly Ile Gly Thr Thr Tyr

1 5

<210>126

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>126

Ile Tyr Thr Gly Asp Gly Ser Thr His

1 5

<210>127

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>127

Ile Ser Ala Gln Gly Val Ile Pro Gly

1 5

<210>128

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>128

Ile Asp Ser Ala Gly Ser Thr Arg

1 5

<210>129

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>129

Ile Arg Ser Gly Gly Gly Asn Thr Tyr

1 5

<210>130

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>130

Ile Ser Arg Ile Asp Asn Ser Thr Tyr

1 5

<210>131

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>131

Phe Val Thr Gly Ala Gly Ser Thr Tyr

1 5

<210>132

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>132

Ile Thr Val Thr Gly Thr Arg Gln Tyr

1 5

<210>133

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>133

Ile Asp Asn Asn Gly Trp Ser Thr

1 5

<210>134

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>134

Ile Asp Thr Asn Gly Ser Thr Ser

1 5

<210>135

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>135

Ile Tyr Arg Asp Gly Ser Ala Pro Tyr

1 5

<210>136

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>136

Ile Tyr Thr Gly Gly Ser Ala Thr Ser

1 5

<210>137

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>137

Ile Cys Ser Asp Gly Ser Ser Ala

1 5

<210>138

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>138

Ile Tyr Thr Gly Ile Gly Ser Thr Tyr

1 5

<210>139

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>139

Ile Gly Tyr Ser Gly Ser Thr Tyr

1 5

<210>140

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>140

Ile Cys Ser Asp Gly Ser Thr Ala

1 5

<210>141

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>141

Ile Thr Phe Thr Gly Arg Thr Leu

1 5

<210>142

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>142

Ile Tyr Thr Asn Val Gly Thr Thr Tyr

1 5

<210>143

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>143

Ile Asp Arg Asp Gly Arg Thr Ser

1 5

<210>144

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>144

Ile His Thr Asp Gly Ser Thr Ser

1 5

<210>145

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>145

Ser Asn Thr Asn Gly Gly Ser Thr Tyr

1 5

<210>146

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>146

Thr Asn Arg Asp Gly Met Ser Tyr

1 5

<210>147

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>147

Val Tyr Asn Asp Gly Gly His Thr Tyr

1 5

<210>148

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>148

Ile Phe Thr Arg Gly Thr Thr Lys

1 5

<210>149

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>149

Leu Tyr Leu Gly Gly Ser Ile Thr Tyr

1 5

<210>150

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>150

Ile Asp Thr Ile Gly Glu Ile Asp

1 5

<210>151

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>151

Leu Asp Gly Asp Gly Arg Val Arg

1 5

<210>152

<211>10

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>152

Ala Ala Ala Trp Arg Pro Pro Cys Val Pro

1 5 10

<210>153

<211>21

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>153

Ala Ala Asp Leu Ser Pro Tyr Asp Cys Tyr Thr Gly Ser Leu Asp Met

1 5 10 15

Ala Ser Arg Phe Thr

20

<210>154

<211>16

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>154

Ala Ala Val Leu Cys Thr Asp Asp Tyr Lys Met Ala Pro Ala Asn Tyr

1 5 10 15

<210>155

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>155

Ala Ala Gly Leu Ala Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Gly Phe Arg Tyr

20

<210>156

<211>12

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>156

Ala Ala Arg Arg Thr Trp His Ala Gly Phe Pro Tyr

1 5 10

<210>157

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>157

Ala Ala Gly Leu Asp Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Gly Phe Arg Tyr

20

<210>158

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>158

Ala Ala Asn Arg Arg Ala Tyr Pro Tyr Gly Gly Asp Cys Arg Leu Arg

1 5 10 15

His Ala Glu Phe Asp Tyr

20

<210>159

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>159

Ala Ala Asp Val Pro Gly Arg Arg Glu Val Arg Gly Leu Gly Pro Cys

1 5 10 15

Asp Arg Met Tyr Asp Tyr

20

<210>160

<211>21

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>160

Ala Ala Lys Val Pro Phe Gly Arg Gly Ser Cys Ala Tyr Ser Thr Ala

1 5 10 15

His Trp Phe Pro Tyr

20

<210>161

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>161

Ala Ala Gly Leu Asp Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Asp

1 5 10 15

Gly Phe Arg Tyr

20

<210>162

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>162

Val Ala Asp Leu Ser Ala Trp Cys Arg Ala Val Arg Pro Gly Val Ile

1 5 10 15

Thr Tyr Asn Tyr

20

<210>163

<211>25

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>163

Ala Ala Asp Pro Arg Asp Pro Asn Gly Ser Arg Thr Asp Cys Thr Val

1 5 10 15

Leu Thr Ser Lys Asp Leu Tyr Asn Ser

20 25

<210>164

<211>13

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>164

Ala Ala Gly Pro Gly Cys Ser Trp Ser Ser Phe Ala Tyr

1 5 10

<210>165

<211>16

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>165

Val Ala Met Thr Trp Asp Gly Thr Cys His Ile Thr Ser Glu Phe Tyr

1 5 10 15

<210>166

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>166

Ala Ala Val Ile Gly Val Asp Ile Arg

1 5

<210>167

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>167

Ala Ile Arg Trp Gly Asp Cys Asp Ser Ala Ser Trp Ser Arg Arg Thr

1 5 10 15

Trp Tyr Ala Val

20

<210>168

<211>23

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>168

Ala Arg Ser Arg Ala Ser Leu Trp Ser Gly Asn Trp Tyr Arg Ser Leu

1 5 10 15

Ser Glu Asp Glu Tyr Asn Ser

20

<210>169

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>169

Ala Ala Gly His Asp Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Asp

1 5 10 15

Gly Phe Arg Tyr

20

<210>170

<211>15

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>170

Ala Ala Ala Asp Ala Gln Arg Gly Arg Thr Cys Phe Phe Gly Ala

1 5 10 15

<210>171

<211>12

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>171

Ala Val Arg Trp Tyr Trp Asp Ala Gly Phe Lys Tyr

1 5 10

<210>172

<211>16

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>172

Ala Ala Gly His Asp Gly Arg Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

<210>173

<211>9

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>173

Ala Ala Val Ile Gly Tyr Asp Ile Arg

1 5

<210>174

<211>25

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>174

Ala Ala Asp Ser Arg Thr Pro Ser Asp Cys Tyr Ser Gly Ser Trp Leu

1 5 10 15

Glu Lys Tyr Pro Ser Glu Tyr Ser Tyr

20 25

<210>175

<211>21

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>175

Ala Ala Asp Val Val Ser Tyr Tyr Ser Asp Tyr Val Cys Thr Asp Ala

1 5 10 15

Ala Asp Phe Gly Tyr

20

<210>176

<211>17

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>176

Ala Ala Gly Thr Thr Arg Leu Gly Ser Leu Leu Ala Pro Thr Tyr Arg

1 5 10 15

Tyr

<210>177

<211>17

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>177

Ala Ala Gly Phe Met Tyr Gly Glu Thr Arg Ser Pro Asn Trp Val Asn

1 5 10 15

Tyr

<210>178

<211>14

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>178

Ala Lys Lys Arg Thr Tyr Asp Cys Tyr Ser Gly Thr Cys Ser

1 5 10

<210>179

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>179

Ala Ala Gly Leu Tyr Gly Gly Ser Pro Tyr Phe Pro Leu Asn Trp Thr

1 5 10 15

Gly Phe Arg Tyr

20

<210>180

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>180

Ala Ala Gly Leu Arg Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Gly Phe Arg Tyr

20

<210>181

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>181

Ala Ala Gly His Asp Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Gly Phe Arg Tyr

20

<210>182

<211>16

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>182

Lys Thr Val Lys Asp Pro Thr Ser Pro Pro Gly Cys Ser Arg Gly Tyr

1 5 10 15

<210>183

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>183

Ala Ala Asp Leu Leu Ile Gly Ala Cys Ser Gln Met Arg Arg Thr Asn

1 5 10 15

Phe Asp Tyr

<210>184

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>184

Ala Ala Asn Pro Tyr Ser Pro Gly Ala Gly Arg Glu Leu Leu Ser Tyr

1 5 10 15

Pro Tyr Thr Asp

20

<210>185

<211>21

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>185

Ala Ala Asn Gln Gly Ser Gly Asp Tyr Cys Tyr Met Ala Met Leu Ile

1 5 10 15

Tyr Gly Met Phe Tyr

20

<210>186

<211>18

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>186

Ala Ala Arg Asp Gly Ser Trp Phe Leu Ser Leu Val Pro Ala Thr Tyr

1 5 10 15

Gly Tyr

<210>187

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>187

Ala Ala Asp Leu Gln Ile Gly Ser Cys Ser Gln Met Arg Arg Tyr Asn

1 5 10 15

Tyr Ala Tyr

<210>188

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>188

Gly Ala Asp Pro Gly Glu Gly Ser Tyr Cys Ala Tyr Glu Ala Pro Glu

1 5 10 15

Val Gly Ala Leu Asp Ile

20

<210>189

<211>14

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>189

Ala Ala Gly Arg Thr Tyr Asp Cys Tyr Pro Gly Thr Cys Ser

1 5 10

<210>190

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>190

Ala Ala Ser Leu Arg Ala Arg Trp Val Gln Arg Gly Ala Pro Leu Leu

1 5 10 15

Pro Ser Phe Tyr Gly Tyr

20

<210>191

<211>17

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>191

Ala Ala Gly Pro Trp Val Ala Thr Pro Glu Ile Ala Asn Glu Tyr Asn

1 5 10 15

Tyr

<210>192

<211>18

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>192

Val Ala Gly Ile Trp Thr Cys Gly Arg Ser Ala Leu Thr Asp Pro Asn

1 5 10 15

Asn Tyr

<210>193

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>193

Ala Ala Thr Phe Gly Leu Phe Trp Glu Ser Trp Glu Trp Tyr Lys Asn

1 5 10 15

Trp His Tyr

<210>194

<211>18

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>194

Ala Ala Asp Pro Gly Val Leu Cys Gly Arg Ser Trp Val Gly Arg Phe

1 5 10 15

Pro Tyr

<210>195

<211>17

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>195

Ala Ala His Gly Ala Phe Ala Ala Arg Asn Asp Pro Arg Gln Trp Arg

1 5 10 15

Tyr

<210>196

<211>17

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>196

Ala Ala Gln Tyr Gly Thr Cys Gln Gly Leu Leu Ser Arg Tyr Phe Ala

1 5 10 15

Tyr

<210>197

<211>25

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>197

Ala Ala Ala His Glu Pro Gly Ser Trp Thr Asp Ile Glu Ala Arg Gly

1 5 10 15

Lys Ile Ser Asp Asp Pro Phe Gly Tyr

20 25

<210>198

<211>13

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>198

Ala Arg Ala Ser Phe Arg Gly Ser Trp Phe Phe Glu Gly

1 5 10

<210>199

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>199

Ala Ala Ala Arg Arg Trp Tyr Tyr Glu Asn Ser Cys Leu Lys Val Leu

1 5 1015

Arg Ser Pro Gly Asp Tyr

20

<210>200

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>200

Ala Ala Gly Pro Pro Ser Gly Pro Leu Arg Ala Cys His Glu Ser Val

1 5 10 15

Phe Gly Tyr

<210>201

<211>16

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>201

Lys Thr Val Arg Asp Pro Ala Ser Pro Pro Ser Cys Ser Gly Gly Tyr

1 5 10 15

<210>202

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>202

Ala Ala Asp Arg Val Leu Gly Arg Cys Ser Arg Arg Leu Leu Ser Asp

1 5 10 15

Phe Gly Tyr

<210>203

<211>18

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>203

Ala Ala Gly Thr Tyr Tyr Ser Asp Tyr Asp Pro Pro Arg Tyr Glu Tyr

1 5 10 15

Lys Tyr

<210>204

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>204

Ala Ala Lys Glu Arg Pro Leu Cys Gly Ser Phe Trp Glu Arg Gly Asp

1 5 10 15

Glu Tyr Ala Ser

20

<210>205

<211>17

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>205

Ala Ala Val Ser Trp Ala Cys Trp Arg Leu Ser Gly Thr Gly Phe Asn

1 5 10 15

Tyr

<210>206

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>206

Ala Ala Asp Leu Gly Val Asp Asp Tyr Ser Asp Tyr Leu Asp His Pro

15 10 15

Phe Gly Tyr

<210>207

<211>29

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>207

Ala Ala Asp Ile Gly Gly Ser Trp Pro Arg Lys Pro His Pro Asp Pro

1 5 10 15

Asn Phe Gly Gly Glu Cys Gly Gly Tyr Gly Met Ala Phe

20 25

<210>208

<211>21

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>208

Ala Ala Asp Ser Ser Ser Leu Pro Cys Tyr Pro Arg Ala Ala Gln Phe

1 5 10 15

Pro Arg Leu Arg Tyr

20

<210>209

<211>26

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>209

Ala Ala Arg Pro Ala Pro Val Ser Gly Ile Thr Arg Phe Arg Leu Asn

1 5 10 15

Arg Ser Leu Leu Pro Asn Glu Tyr Asn Ser

20 25

<210>210

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>210

Ala Ala Gly Leu Asp Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Asn Phe Arg Tyr

20

<210>211

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>211

Ala Ala Glu Gly Gly Trp Arg Asp Tyr Val Arg Ser Trp Gly Arg Asn

1 5 10 15

Phe Gly Tyr

<210>212

<211>23

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>212

Ala Ala Asp Leu Trp Arg Gly Pro Pro Phe Gly Gly Tyr Trp Ser Pro

1 5 10 15

Thr Lys Ser Glu Phe Ala Tyr

20

<210>213

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>213

Ala Ala Asn Arg Arg Ala Tyr Pro Tyr Gly Gly Asp Cys Arg Val Arg

1 5 10 15

His Ala Glu Phe Asp Tyr

20

<210>214

<211>21

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>214

Ala Ala Arg Phe Arg Ala His Asp Gly Tyr Trp Asn Trp Gln Asn Ala

1 5 10 15

Gly Asn Tyr Asn Tyr

20

<210>215

<211>12

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>215

Ala Ala Arg His Tyr Trp Ser Ala Gly Phe Pro Tyr

1 5 10

<210>216

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>216

Ala Ala Asp Arg Val Leu Gly Arg Cys Ser Arg Arg Ile Leu Ser Asp

1 5 10 15

Phe Gly Tyr

<210>217

<211>14

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>217

Ala Arg Ser Ser Pro Arg Thr Val Val Ala Gly Phe Gly Asp

1 5 10

<210>218

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>218

Ala Ala Gly Leu Asp Gly Gly Asn Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Gly Phe Arg Tyr

20

<210>219

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>219

Ala Arg Gly Pro Phe Gly Cys Tyr Ser Val Ser Gly Cys Tyr Arg Lys

1 5 10 15

Gly Gly Val Asp Asn Tyr

20

<210>220

<211>16

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>220

Lys Thr Val Arg Asp Pro Thr Ser Pro Arg Ser Cys Ser Gly Gly Tyr

1 5 10 15

<210>221

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>221

Ala Ala Tyr His Ser Gly Ser Trp Cys Tyr Leu Pro His Leu Gly Ser

1 5 10 15

Tyr Gly Tyr

<210>222

<211>15

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>222

Ala Ala Gly Trp Arg Leu Ser Leu Arg Val Ser Asp Phe Asn Tyr

1 5 10 15

<210>223

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>223

Ala Ala Ser Phe Arg Pro Thr Trp Phe Cys Arg Gly Leu Ala Pro Tyr

1 5 10 15

Lys Tyr Asn Leu

20

<210>224

<211>19

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>224

Thr Ser Ala Ser Leu Thr Trp Asp Gly Gly Asn Trp Tyr Cys Pro Thr

1 5 10 15

His Gly Tyr

<210>225

<211>14

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>225

Ala Ala Gly Arg Thr Tyr Asp Cys Tyr Ser Gly Thr Cys Ser

1 5 10

<210>226

<211>11

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>226

Ala Ala Gly Ala Tyr Arg Ala Ser Phe Thr Tyr

1 5 10

<210>227

<211>11

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>227

Asn Thr Met Trp Gly Ala Arg Gln Asn Lys Asp

1 5 10

<210>228

<211>22

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>228

Ala Ala Asn Arg Arg Pro Tyr Pro Tyr Gly Gly Asp Cys Arg Leu Arg

1 5 10 15

His Ala Glu Phe Asp Tyr

20

<210>229

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>229

Ala Ala Gly Leu Asp Gly Gly Ser Gly Tyr Leu Pro Leu Ala Trp Ala

1 5 10 15

Gly Phe Arg Tyr

20

<210>230

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>230

Ala Ala Gly Leu Asp Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Arg Phe Arg Tyr

20

<210>231

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>231

Ala Ala Gly Val Ala Gly Gly Ser Gly Tyr Leu Pro Leu Asn Trp Ala

1 5 10 15

Gly Phe Arg Tyr

20

<210>232

<211>20

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>232

Ala Ala Gly Phe Ala Gly Cys Tyr Gly Ser Ser Trp Tyr Gly Ser Ala

1 5 10 15

Asp Phe Gly Tyr

20

<210>233

<211>8

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>233

Xaa Xaa Xaa Ser Thr Ala Tyr Tyr

1 5

<210>234

<211>25

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>234

Gln Val Arg Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Glu

1 5 10 15

Thr Leu Arg Leu Ser Cys Thr Ala Ser

20 25

<210>235

<211>17

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>235

Met Gly Trp Tyr Arg Gln Gly Pro Gly Asn Glu Cys Glu Met Val Ala

1 5 10 15

Tyr

<210>236

<211>36

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>236

Ala Asp Ser Thr Lys Gly Arg Phe Thr Ile Ser Gln Asp Asn Ala Lys

1 5 10 15

His Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly

20 25 30

Val Tyr Tyr Cys

35

<210>237

<211>10

<212>PRT

<213> Artificial Sequence (Artificial Sequence)

<400>237

Gly Gln Gly Thr Arg Val Thr Val Ser Ser

1 5 10

Claims

1. An SFTSV detection kit is characterized by comprising a detection antibody, a solid matrix and a coating antibody coated on the solid matrix, wherein the detection antibody and the coating antibody respectively comprise 3 complementarity determining regions CDR1-3, the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NO. 1-74, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NO. 75-151, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO. 152-232.

2. The kit of claim 1, wherein the CDR sequences of the detection antibody are as follows:

the sequence of CDR1 is SEQ ID NO. 4, the sequence of CDR2 is SEQ ID NO. 84, and the sequence of CDR3 is SEQ ID NO. 181;

or the sequence of CDR1 is SEQ ID NO. 54, the sequence of CDR2 is SEQ ID NO. 132, and the sequence of CDR3 is SEQ ID NO. 176;

or the sequence of CDR1 is SEQ ID NO. 13, the sequence of CDR2 is SEQ ID NO. 99, and the sequence of CDR3 is SEQ ID NO. 166.

3. The kit of claim 1, wherein the CDR sequences of the coated antibody are as follows:

The sequence of CDR1 is SEQ ID NO 6, the sequence of CDR2 is SEQ ID NO 81, and the sequence of CDR3 is SEQ ID NO 158; or

4. The kit according to any one of claims 1 to 3,

I) the CDR sequences of the detection antibody are as follows: the sequence of CDR1 is SEQ ID NO. 4, the sequence of CDR2 is SEQ ID NO. 84, and the sequence of CDR3 is SEQ ID NO. 181; or the sequence of CDR1 is SEQ ID NO 13, the sequence of CDR2 is SEQ ID NO 99, and the sequence of CDR3 is SEQ ID NO 166; and the number of the first and second electrodes,

5. The kit according to claim 4,

II) the CDR sequences of the coated antibody are as follows: the sequence of CDR1 is SEQ ID NO:54, the sequence of CDR2 is SEQ ID NO:132, and the sequence of CDR3 is SEQ ID NO: 176; or the sequence of CDR1 is SEQ ID NO 13, the sequence of CDR2 is SEQ ID NO 99, and the sequence of CDR3 is SEQ ID NO 166.

6. The kit according to claim 4,

7. The kit according to claim 4,

the sequence of the detection antibody CDR1 is SEQ ID NO 13, the sequence of the CDR2 is SEQ ID NO 99, and the sequence of the CDR3 is SEQ ID NO 166; and the sequence of the coating antibody CDR1 is SEQ ID NO:54, the sequence of CDR2 is SEQ ID NO:132, and the sequence of CDR3 is SEQ ID NO: 176.